Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Drug Discovery
- Stem cells
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 308740
SL-401 is a clinically active biologic-drug conjugate comprised of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor, or IL-3R, which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. In contrast, IL-3R is not expressed on normal bone marrow stem cells that form the components of blood. SL-401 demonstrated single agent anti-tumor activity in a completed Phase 1/2 clinical trial of 76 patients with advanced hematologic cancers, including 57 patients with relapsed or refractory AML. With only a single cycle of treatment, SL-401 induced either a reduction in leukemia blasts (i.e., tumor bulk) or disease stabilization in 47% (27/57) of relapsed or refractory AML patients.
This compound is being developed to treat patients with AML and other hematologic cancers.
U.S. Provisional Application No. 60/843,471
U.S. Provisional Application No. 60/932,772
U.S. Non-Provisional Application No. 11/899,747
U.S. Non-Provisional Application No. 12/368,048
IPSCIO Record ID: 7534
BL-8040 (formerly BKT-140) is for the treatment of acute myeloid leukemia, as well as other types of hematological cancer (the â€œDrugâ€).
BL-8040, is a novel short peptide that functions as a high-affinity antagonist for CXCR4, which we intend to develop for AML, and other hematological indications. BL-8040 mobilizes cancer cells from the bone marrow and may therefore sensitize these cells to chemo- and bio-based anti-cancer therapy. In addition, BL-8040 has demonstrated a direct anti-cancer effect by inducing apoptosis (cell death). Multiple pre-clinical studies have shown the safety and efficacy of BL-8040. BL-8040 also mobilizes stem cells from the bone marrow to the peripheral blood, enabling their collection for subsequent autologous or allogeneic transplantation in cancer patients.
IPSCIO Record ID: 259856
Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer.
Licensor is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Licensor's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.
IPSCIO Record ID: 319042
Uproleselan is a glycomimetic drug candidate and a specific E-selectin inhibitor that is being developed to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.
E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering the circulation where they can be more readily killed by chemotherapy. Glycomimetics are molecules that mimic the structure of carbohydrates involved in biological processes.
IPSCIO Record ID: 360156
Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia (acute lymphocytic (ALL), chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma, and lymphoma (Hodgkin's and non-Hodgkin's (NHL)).
IPSCIO Record ID: 336338
Licensor is the co-owner with a Hospital Corporation of certain Patent Rights. The patents are Method to Modulate Hematopoietic Stem Cell Growth, and, Method to Enhance Tissue Regeneration.
ZON IND shall mean the investigational new drug application titled A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Ex-Vivo 16,16 Dimethyl-Prostaglandin E2 Expanded Umbilical Cord Blood Units.
Licensee's lead product candidate, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood. Licensee has established human proof-of-concept for ProHema in the clinical setting by demonstrating enhanced and durable engraftment of HSCs within the bone marrow. Engraftment, which is the localization and integration of HSCs within a targeted tissue where they can produce new cells, is an important determinant of patient outcomes in HSCT. Licensee is presently advancing ProHema in Phase 2 clinical development for hematologic malignancies. Licensee is also pursuing the development of pharmacologically optimized HSC therapeutics for the treatment of certain lysosomal storage disorders, or LSDs, where HSCs have demonstrated the ability to home, or migrate, to and engraft within the central nervous system, or CNS.
IPSCIO Record ID: 362432
This agreement includes a non-exclusive grant back from Licensee to Licensor.
Licensors Dimerizer shall mean the compound known as xx1903, all analogs and derivatives of xx1903 and any Dimerizcr or salt thereof, where the composition of matter thereof or its use as a divalent ligand is, at any time during the Primary License Term, within the scope of a claim in any patent or patent application within the Licensed Patent Rights.
xx1903 is for the treatment of GvHD as an orphan drug.
GvHD shall mean a clinical condition involving acute or chronic adverse effects or symptoms resulting from the allogenic transplantation of bone marrow, hematopoietic or stem cells into a human being in which engrafted donor cells attack the patients organs and tissues which can be treated by activating cell signaling leading to apoptosis of the transplanted cells.
Cell Transplantation Indication shall mean GvHD or any other acute or chronic adverse clinical effect in a human being resulting from transplantation of bone marrow, hematopoietic or stem cells that can be treated by inducing apoptosis of transplanted cells, or in the case of a bone marrow, hematopoietic or stem cell product for transplantation that includes cells containing a gene coding for an Inducible Caspase, any disease or condition in a human being that can be treated by such product.
Licensed Products include BPX-101 (formerly BP-GMAX-CDJ) , and, CaspaCIDe Donor Lymphocyte Infusion.
Licensee is developing cell therapies to treat cancers and other chronic and life-threatening diseases.
IPSCIO Record ID: 383612
Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.
Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.
Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.
Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.
COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.
Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.
Crohns Indication shall mean the use of Prochymal to treat Crohns disease.
Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.
GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.
Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.
Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.
IPSCIO Record ID: 26488
IPSCIO Record ID: 369402
University grants an exclusive option to negotiate a worldwide, exclusive license to any Improvements made within two years of the effective date.
This agreement includes non-exclusive grant back to Licensor by Licensee.
Novel Mechanistically Altered Tyrphostins with Potent Antitumor Activity, and,
Compounds for Treatment of Cell Proliferative Diseases.
Licensee is a biopharmaceutical company focused on the development of drugs to treat relapsed (re-occurrence of active disease) or refractory acute leukemia, multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and advanced carcinoid cancer patients.